CD305 (LAIR-1) Antibody, anti-human, REAfinity™
Synonyms: hLAIR1, CD305, LAIR-1
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
2 Citations1 Image
Clone:
REA447 | NKTA255
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD305 (LAIR-1) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 770
Vio Bright FITC
Vio Bright R720
Species tested:
human
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-134-166, 130-134-111
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with CD305 (LAIR-1) antibodies or with the corresponding REA Control (S) antibodies (left image) as well as with CD19 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. Lymphocytes were pregated for the analysis. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
human
Tissue used:
spleen
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-134-166, 130-134-111
Testing grade:
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human spleen. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using CD305 (LAIR-1) Antibody, anti-human, APC (green) for 10 min at room temperature.
Fixation:
FFPE
Species tested:
human
Tissue used:
spleen
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-134-166, 130-134-111
Testing grade:
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin-embedded (FFPE) tonsil section. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using CD305 (LAIR-1) APC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.    

Application image
Extended validation for CD305 (LAIR-1) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA447
DX26
high
NKTA255
high
QA19A19
high

Cells were incubated with an excess of purified unconjugated CD305 (LAIR-1) (REA447) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD305 (LAIR-1) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD305 (LAIR-1)-PE (REA447, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD305 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD305-PE, clone (REA447). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD305. PBMCs were stained with CD305 antibodies and with a suitable counterstaining. As a control, CD305 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for CD305 (LAIR-1) Antibody, anti-human, REAfinity™
Overview

Clone REA447 recognizes the human CD305 antigen, a single-pass type I membrane protein which is also known as leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1). CD305 contains a single extracellular immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory motifs. It is structurally related to several other inhibitory Ig superfamily members. CD305 is expressed on almost all immune cells, including NK cells, T cells, B cells, monocytes, monocyte-derived dendritic cells, eosinophils, basophils, and mast cells. Besides being expressed on differentiated peripheral blood cells, the receptor is also present on CD34+ hematopoietic progenitor cells and on the majority of thymocytes. Cross-linking of CD305 on human NK cells delivers a potent inhibitory signal that is capable of inhibiting target cell lysis by resting and activated NK cells. Furthermore, CD305 can inhibit the cytotoxic activity of effector T cells upon CD3 cross-linking or antigen stimulation. In primary B cells, CD305 cross-linking leads to decreased BCR-induced calcium mobilization and down-regulation of Ig and cytokine production.

Additional information: Clone REA447 displays negligible binding to Fc receptors.

Alternative names

hLAIR1, CD305, LAIR-1

Detailed product information

Technical specifications

Clone
REA447
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD305 (LAIR-1)
Molecular mass of antigen [kDa]
28
Distribution of antigen
B cells, dendritic cells, monocytes, NK cells, mast cells, T cells, basophils, eosinophils, thymocytes
Entrez Gene ID
RRID
AB_2928397, AB_2857839, AB_2657227, AB_2857836, AB_2928398, AB_2657222, AB_2657228, AB_2657230, AB_2657229, AB_2657221

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD305 (LAIR-1) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support